{"organizations": [], "uuid": "cb7bf4d8ab7c217c1001b763e220d04ca07dc920", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-astrazeneca-disappointed-by-data-f/brief-astrazeneca-disappointed-by-data-from-arctic-trial-in-third-line-non-small-cell-lung-cancer-idUSFWN1S106S", "country": "US", "domain_rank": 408, "title": "BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.69, "site_type": "news", "published": "2018-04-24T14:17:00.000+03:00", "replies_count": 0, "uuid": "cb7bf4d8ab7c217c1001b763e220d04ca07dc920"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-astrazeneca-disappointed-by-data-f/brief-astrazeneca-disappointed-by-data-from-arctic-trial-in-third-line-non-small-cell-lung-cancer-idUSFWN1S106S", "ord_in_thread": 0, "title": "BRIEF-AstraZeneca disappointed by data from Arctic trial in third-line non-small cell lung cancer", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "astrazeneca plc", "sentiment": "negative"}, {"name": "london newsroom", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " AstraZeneca PLC:\n* REPORTS RESULTS FROM ARCTIC TRIAL IN THIRD-LINE NON-SMALL CELL LUNG CANCER\n* WHILE WE ARE DISAPPOINTED THAT COMBINATION OF IMFINZI PLUS TREMELIMUMAB DID NOT RESULT IN A STATISTICALLY-SIGNIFICANT SURVIVAL BENEFIT IN THIS HEAVILY PRE-TREATED PATIENT POPULATION, WE ARE ENCOURAGED BY ACTIVITY OF IMFINZI MONOTHERAPY OBSERVED IN THIS TRIAL\n* FULL DATA FROM ARCTIC TRIAL WILL BE PRESENTED AT A FORTHCOMING MEDICAL MEETING Source text for Eikon: Further company coverage: (London Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-24T14:17:00.000+03:00", "crawled": "2018-04-25T14:23:47.000+03:00", "highlightTitle": ""}